Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.
Promotions and hires for agencies and manufacturers
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.
Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."
Perceptions of vaccines impact consumers' purchasing decisions
Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.
AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.
Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.
Resignations stymied the Office of Pharmaceutical Quality's beginning.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.